UroCor to launch ProstaSeed in US:
This article was originally published in Clinica
Executive Summary
UroCor is to launch its radioactive source for treatment of prostate cancer, ProstaSeed I-125, throughout the US, with its marketing and distribution partners Mallinckrodt and Prostate Services of America. Oklahoma City, Oklahoma-based UroCor claims to be the only medical company involved in the treatment of prostate cancer with the ability to support both the urologist and the radiation oncologist in diagnosing and managing the patient's condition. Some 200,000 new cases of prostate cancer are diagnosed annually in the US, around 60% of which are potentially treatable by brachytherapy, the company says.